Biogen’s 2000 Press Releases

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.

2003 | 2002 | 2001 | 2000 Back to main index

12/18/2000

BIOGEN ANNOUNCES THAT BOARD OF DIRECTORS AUTHORIZES REPURCHASE OF UP TO 4,000,000 SHARES OF COMMON STOCK

12/18/2000

BIOGEN SCIENTISTS DEMONSTRATE ON A GENOME-WIDE BASIS THAT THE EXTRACELLULAR MATRIX REGULATES GENE EXPRESSION

12/06/2000

BIOGEN EXECUTES LICENSE AGREEMENT WITH NSGENE A/S FOR NOVEL NEUROTROPHIC PROTEIN

10/17/2000

AVONEX® (Interferon beta-1a) SHOWN TO BE MOST POTENT INHIBITOR FOR KEY MULTIPLE SCLEROSIS ANTIBODY

10/12/2000

BIOGEN APPOINTS PROFESSOR CORNELIS LUCAS AS DIRECTOR, INTERNATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT

10/10/2000

BIOGEN REPORTS THIRD QUARTER RESULTS

10/06/2000

BIOGEN ANNOUNCES REALIGNMENT OF MANAGEMENT POSITIONS

09/20/2000

BIOGEN SAYS THAT JUDGE ENTERS FINAL JUDGMENT ON ALL CLAIMS IN BERLEX LAWSUIT

09/13/2000

BIOGEN AND EOS BIOTECHNOLOGY ANNOUNCE GENOMIC TARGET AND THERAPUTIC ANTIBODY COLLABORATION

08/17/2000

BIOGEN AND ELAN TO COLLABORATE ON DEVELOPMENT AND COMMERCIALIZATION OF ANTEGREN® (natalizumab)

08/15/2000

BIOGEN PRAISES COURT RULING THAT AVONEX® DOES NOT INFRINGE BERLEX

08/09/2000

BIOGEN AND TARGETED GENETICS TO COLLABORATE ON GENE THERAPY RESEARCH

07/11/2000

BIOGEN REPORTS SECOND QUARTER 2000 RESULTS

07/10/2000

BIOGEN APPOINTS PETER N. KELLOGG VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER